PCI-32765 down-regulates CCL3 and CCL4 secretion in vitro (in NLC cocultures) and in vivo in plasma samples of CLL patients undergoing therapy with PCI-32765. (A) Incubation with PCI-32765 significantly inhibits the secretion of CCL3 and CCL4 in CLL-NLC cocultures. The bars in this graph represent mean ± SEM CCL3 (left graph) and CCL4 (right graph) concentrations in supernatants of CLL-NLC cocultures from 11 different CLL samples in pg/mL. *P ≤ .05. (B) CCL3 (left graph) and CCL4 (right graph) plasma concentrations in CLL patients before and during therapy with PCI-32765. Displayed are individual plasma concentrations, indicated by the dots, and mean ± SD plasma concentrations, as indicated by the horizontal lines. CCL3 and CCL4 plasma concentrations were measured at the time points indicated on the horizontal axes. * indicates significant changes with P ≤ .05.